These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2326771)

  • 21. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
    Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
    Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective effects of thromboxane A2 synthetase inhibitors on endotoxin shock.
    Fukumoto S; Tanaka K
    Prostaglandins Leukot Med; 1983 Jun; 11(2):179-88. PubMed ID: 6576388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of platelet activating factor antagonist (CV-3988) on 6-keto-PGF1 alpha and thromboxane B2 in dogs with experimental endotoxin-induced shock.
    Okano S; Tagawa M; Urakawa N
    J Vet Med Sci; 1995 Feb; 57(1):81-5. PubMed ID: 7756431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thromboxane and prostacyclin in endotoxin-induced lung injury].
    Hu S
    Zhonghua Jie He He Hu Xi Za Zhi; 1990 Feb; 13(1):15-7, 61. PubMed ID: 2199081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications for thromboxane A2 in the pathogenesis of endotoxic shock.
    Wise WC; Cook JA; Halushka PV
    Adv Shock Res; 1981; 6():83-91. PubMed ID: 6961767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis.
    Altavilla D; Squadrito F; Canale P; Ioculano M; Squadrito G; Campo GM; Serranò M; Sardella A; Urna G; Spignoli G
    Eur J Pharmacol; 1995 Nov; 286(1):31-9. PubMed ID: 8566149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by oral administration.
    Nakashima M; Uematsu T; Takiguchi Y; Mizuno A; Kanamaru M
    J Clin Pharmacol; 1989 Jun; 29(6):568-76. PubMed ID: 2754025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of a specific thromboxane synthetase inhibitor in equine endotoxaemia.
    Semrad SD; Moore JN
    Res Vet Sci; 1987 Sep; 43(2):137-42. PubMed ID: 3317581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
    Hardee MM; Moore JN; Hardee GE
    Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of lipoxygenase (LOX) or of cyclooxygenase (COX) improves survival of rats in endotoxin shock.
    Schaper U; Lueddeckens G; Förster W; Scheuch DW
    Biomed Biochim Acta; 1988; 47(10-11):S282-5. PubMed ID: 3150270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic and cardiovascular effects of endotoxin infusion in conscious unrestrained rats: effects of methylprednisolone and BW755C.
    McKechnie K; Furman BL; Parratt JR
    Circ Shock; 1985; 15(3):205-15. PubMed ID: 3919962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
    Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
    Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of glycerol-induced acute renal failure in rabbit with Ligusticum wallichii on thromboxane B2, 6-keto-prostaglandin F1 alpha/thromboxane B2].
    Hu WL; Ma YJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 Sep; 13(9):549-50, 518. PubMed ID: 8111216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of cyproheptadine on TXB2 and 6-keto-PGF1 alpha plasma levels in rabbits with hemorrhagic shock.
    Zhang QZ; Wang Q; Zhang CF; Ling XZ; Liu WY; Jin LY
    Zhongguo Yao Li Xue Bao; 1994 May; 15(3):226-8. PubMed ID: 7976376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of thromboxane and prostacyclin in endotoxic and septic shock.
    Cook JA; Wise WC; Butler RR; Reines HD; Rambo W; Halushka PV
    Am J Emerg Med; 1984 Jan; 2(1):28-37. PubMed ID: 6440569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
    Dodd NJ; Gordge MP; Weston MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):67S-70S. PubMed ID: 6337605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death.
    Edmonds LC; Lefer AM
    Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Changes in platelet aggregation, TXB2 and 6-keto-PGF1 alpha in surgical shock].
    Tian L
    Zhonghua Wai Ke Za Zhi; 1990 Jun; 28(6):339-41, 381. PubMed ID: 2096057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The survival of pig to rabbit renal xenografts during inhibition of thromboxane synthesis.
    Jørgensen KA; Kemp E; Barfort P; Starklint H; Larsen S; Petersen PH; Knudsen JB
    Thromb Res; 1983 Dec; 32(6):585-91. PubMed ID: 6364449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.